Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Sep 09, 2011 4:42pm
629 Views
Post# 19027981

Is Hans Black going to be exiting the board ?

Is Hans Black going to be exiting the board ?With the announcement of a new board member, will we see one exiting or just an increase ? Could it be in the not to distant future that Dr. Hans Black leaves the Amorfix board of directors, may-be knowing full well what Amorfix has in it's product pipeline. If we look back over the last year, as reported on August 16, 2010. Dr. Hans Black The Chairman of Interinvest also a director of Amorfix has acquired through open market purchases a total of 4,862,550 common shares of Amorfix representing 10% of the issued and outstanding common shares. As DR. Gundel commented " We appreciate this strong endorsement of Amorfix by Interinvest  and our Directors who share our vision and confidence in our product pipeline and it's future prospects." From August 2010 to present it appears Interinvest has been upholding this confidence on a monthly basis with as many as eight different buying days in July 2011. !!
A different area Dr. Hans Black may have contributed: If you refer to MD&A for the year ended March 31,2011, under Related Party Transactions. " A company controlled by a director of Amorfix provides Investment Advisory Services to Amorfix. The Company paid $18,620 to a company over which a director has significant influence, for legal and consulting services related to the February 28, 2011 private placement offering."
Hard to say what's going to happen if Dr. Hans Black does exit, probably means he will no longer be an insider and these types of transactions will no longer have to be reported.
Bullboard Posts